针对LSD1的SP2577和TCP的合成和结构-活性研究针对PROTACs
Megan E Coulson1,2, James K S Norris1, Sean A Smith1
1Leicester Institute of Structural and Chemical Biology and School of Chemistry, University of Leicester University Road Leicester LE1 7RH UK JTHodgkinson@le.ac.uk.
RSC medicinal chemistry
|August 7, 2025
概括
研究人员探索了针对LSD1进行表观遗传调节的新型PROTACs. 虽然在细胞中没有发现降解剂,但两种类型在体外显示出强大的LSD1抑制,为药物开发提供了关键的结构-活性见解.
科学领域:
- 表观遗传学和分子生物学
- 药物发现和药物化学
背景情况:
- 氨酸特异性基因组脱甲酶1A (LSD1) 是一个关键的表观遗传调节剂,也是一个有前途的药物标.
- 目前,一些LSD1抑制剂正在临床试验中.
研究的目的:
- 根据已知的LSD1抑制剂 (TCP和SP2577) 合成和评估异构生物功能分子 (PROTAC).
- 为了研究结构-活动关系 (SAR),开发新的针对LSD1的PROTACs.
主要方法:
- 合成了16种包含TCP和SP2577支架的异构生物功能分子.
- 在体外酶定量测试以评估LSD1抑制.
- 在HCT116细胞中进行基于细胞的测试,以评估LSD1降解.
主要成果:
- 在HCT116细胞中没有发现LSD1降解剂.
- 两种TCP类似物,用基和PEG连接器和VHL连接体功能化,在体外表现出强大的LSD1抑制 (43nM和63nM) 对HDAC1-CoREST-LSD1复合体.
结论:
- 这项研究为LSD1 PROTACs的发展提供了关键的SAR数据.
- 在TCP支架上的特定修改可以导致强大的体外LSD1抑制剂,为进一步的PROTAC开发铺平道路.
相关概念视频
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.2K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
649
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
649
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.4K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.4K
Local Anesthetics: Chemistry and Structure-Activity Relationship
5.4K
Local anesthetics (LAs) are drugs that induce a temporary loss of sensation in a limited body area, preventing pain. Cocaine was the first local anesthetic discovered in the late 19th century. Cocaine is a benzoic acid ester obtained from the leaves of coca shrubs and was often used for its psychotropic effects. Cocaine was first isolated in 1860 by Albert Niemann. Sigmund Freud studied the physiological actions of cocaine. Carl Koller later introduced it into clinical practice in 1884 as a...
5.4K


